We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

The Effect of Urox™ in the Treatment of Overactive Bladder and Urinary Incontinence

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02396160
Recruitment Status : Completed
First Posted : March 24, 2015
Results First Posted : May 5, 2016
Last Update Posted : May 5, 2016
University of Tasmania
Seipel Group Pty Ltd
Endeavour College of Natural Health
Information provided by (Responsible Party):
Dr Niikee Schoendorfer, The University of Queensland

Brief Summary:
This study aims to assess the efficacy of a specialized herbal formula, Urox, versus control over 8 weeks, in a double blind, placebo controlled trial. 150 participants are being recruited, randomized and administered treatment or placebo for the period of 8 weeks after initial eligibility screening. Outcome measures include previously validated tools such as the 3 day symptom diary measuring self-recorded day frequency, nocturia, urgency and incontinence episodes. Quality of life improvements are being measured using the Incontinence Impact Questionnaire, Urinary Distress Inventory and the short version of the OverActive Bladder survey.

Condition or disease Intervention/treatment Phase
Overactive Bladder Urinary Incontinence Urinary Frequency or Urgency Adverse Event Nocturia Dietary Supplement: Urox Other: Placebo Not Applicable

Detailed Description:

Initial consultations were held at either the Brisbane campus of the Endeavour College of Natural Medicine Naturopathic clinic or at Kelvin Grove Natural Medicine clinic, Brisbane. Follow up interviews are being conducted via telephone. To minimize dropout rates, participants are telephoned (as a reminder for the call and to complete the micturition diaries) approximately 1 week before the scheduled interview time and were intermittently called over the week following if they were unable to be reached at the scheduled interview time. Three attending clinicians interviewed trial participants, all having participated in interview training prior to any interviews being taken. The training was designed to ensure utility of a uniform and consistent approach regarding how questions were asked and how data was recorded.

The week prior to an initial consultation participants were requested to complete a micturition diary and health related quality of life surveys, to serve as baseline measures. The attending clinician then also completed a clinical data sheet, at the time of the initial consultation, containing a range of questions including demographics, exercise, health history and habits, which will be used to control and correlate data variables. Any incomplete quality of life surveys at the outset were also completed at the first interview.

Micturition diaries are collected by post at 2, 4 and 8 week intervals along with the completion of quality of life surveys and follow up clinical data sheet via telephone. Participants were asked to keep the micturition diary for 3 days prior to each consultation and were provided reply paid envelopes to return the surveys and unused capsules to assess compliance.

For the primary outcome (day frequency) measure it was calculated that 90 participants equally divided into placebo and control were required to detect a difference of 1.6 urinary frequency episodes per day (2.7SD) between treatment and placebo groups, with a two-tailed alpha of 0.05 and a power of 80%. For total incontinence, 53 participants were required equally divided into each group to detect a difference of 1.2 episodes per day (2.2SD), while for urgency 54 was required in each group to detect a difference of 2 per day (3.7SD). To account for potential drop-outs and variations in presenting symptoms, a total of 150 participants were recruited.

Data for the two treatments will be compared using mixed effects ordered logistic regression adjusted for repeated measures (Stata, version 13.1, StataCorp, TX, USA). GraphPad Prism (version 6.00 for Windows, GraphPad Software, La Jolla California, USA) will be used to plot the data. Data (day frequency, night frequency, urgency and incontinence) will be evaluated by intention to treat analysis, with the last result brought forward for people who dropped out or were lost to follow-up. Variables selected for adjustment using backward stepwise regression from list including age, sex, water intake and diuretic use (p<0.22 for covariate inclusion). Holm estimation test will be used to adjust p-values for repeated measures. Each analysis will only included participants who are symptomatic at baseline. For example, in relation to daytime urinary frequency - only participants with baseline of ≥10 will be included in the analyses.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 150 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: The Effect of Urox™(Crateva, Horsetail and Lindera Combination) in the Treatment of Overactive Bladder and Urinary Incontinence
Study Start Date : August 2013
Actual Primary Completion Date : December 2014
Actual Study Completion Date : May 2015

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: Treatment
2 capsules per day of the herbal formula (Urox®) with each capsule containing 420mg of a concentrated proprietary blend of extracts of Crateva nurvala stem bark, Equisetum arvense stem and Lindera aggregata root
Dietary Supplement: Urox
Active treatment - Proprietary combination of Crateva nurvala, Equisetum arvense and Lindera aggregata herbs

Placebo Comparator: Placebo
identical placebo vegetarian capsule containing color-matched cellulose
Other: Placebo
Placebo - Identical vegetarian capsule containing color-matched cellulose to that of the active treatment

Primary Outcome Measures :
  1. Day Urinary Frequency [ Time Frame: 8 weeks ]
    Day urinary frequency as defined as the number of voluntary diurnal micturitions per day, recorded in a validated urinary diary

  2. Nocturia Frequency [ Time Frame: 8 weeks ]
    Night time urinary frequency as defined as the number of voluntary nocturnal micturition's per day recorded in a validated urinary diary

Secondary Outcome Measures :
  1. Urinary Urgency Frequency [ Time Frame: 8 weeks ]
    Urinary urgency as defined by number of urgency episodes per day recorded in a validated urinary diary

  2. Urge Incontinence Frequency [ Time Frame: 8 weeks ]
    Urge incontinence as defined by number of incontinence episodes per day resulting from urinary urgency, recorded in a validated urinary diary

  3. Stress Incontinence Frequency [ Time Frame: 8 weeks ]
    Stress incontinence as defined by number of episodes of incontinence per day related to stress, recorded in a validated urinary diary

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Inclusion criteria include symptoms of urinary frequency (at least ten times per day) and/or incontinence (at least nine episodes per week), provided they have experienced symptoms of OAB for at least 6 months.

Exclusion Criteria:

  1. Recent surgery particularly hysterectomy or prolapse repair (within the last 12 months)
  2. Recently undergone childbirth (within the last 12 months), or currently pregnant.
  3. Use of any natural therapies for bladder symptoms in the last month.
  4. Concomitant health conditions such as uncontrolled diabetes mellitus, heart disease, pancreatic, hepatic or renal disease, recurrent urinary tract infections, and chronic inflammatory conditions, which may otherwise affect outcomes.
  5. Currently being treated for mental health issues or psychiatric disturbances.
  6. Any individuals who are presently taking prescribed medication for incontinence or OAB.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02396160

Sponsors and Collaborators
The University of Queensland
University of Tasmania
Seipel Group Pty Ltd
Endeavour College of Natural Health
Layout table for investigator information
Principal Investigator: Niikee Schoendorfer, PhD The University of Queensland
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Dr Niikee Schoendorfer, Research Fellow, The University of Queensland
ClinicalTrials.gov Identifier: NCT02396160    
Other Study ID Numbers: SG-04
First Posted: March 24, 2015    Key Record Dates
Results First Posted: May 5, 2016
Last Update Posted: May 5, 2016
Last Verified: April 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: As data was analysed de-identified, it is not possible to have individual participant data available associated with their name and details.
Keywords provided by Dr Niikee Schoendorfer, The University of Queensland:
overactive bladder
urinary incontinence
urinary frequency
Additional relevant MeSH terms:
Layout table for MeSH terms
Urinary Incontinence
Urinary Bladder, Overactive
Urination Disorders
Urologic Diseases
Lower Urinary Tract Symptoms
Urological Manifestations
Behavioral Symptoms
Elimination Disorders
Mental Disorders
Urinary Bladder Diseases